Pharmaceuticals, Biotechnology and Life Sciences
Boehringer Ingelheim has bought Northern Biologics Inc., a wholly owned subsidiary of Northern LP, whose programs targeting the tumor microenvironment are the latest in a series of strategic acquisitions and collaborations that strengthen Boehringer Ingelheim’s position in cancer immunology,
Medicago, a biopharmaceutical company headquartered in Quebec City, announced today that its vaccine candidate for COVID-19 induced a positive antibody response only 10 days after a single dose in mice.
Data reveal reductions in annual infections and warts, and sustained dose-dependent increases in neutrophil counts These and additional Phase 2…
The results of this study provide evidence of the potential benefit of MK-6482 and support further investigation into how this HIF-2α inhibitor could play a meaningful role for these patients
Schrödinger has reported a total revenue of $26.2 million and strong growth of 26% year-over-year, with record software revenue of $23.8 million, up 28% year-over-year, while it also raised $209.6 million in net proceeds through initial public offering.
Novocure’s Optune has became the first innovative treatment for glioblastoma approved in China in over 15 years, the company said in a Wednesday press release, after it’s global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rate.
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Sunovion Pharmaceuticals Inc. (Sunovion) said Wednesday in a press release that it has withdrawn the New Drug Applications…
Takeda has reported FY2019 revenue JPY 3,291 billion ($30.75M), up 57% in first full year following acquisition of Shire.
Gossamer Bio has reported a net loss for the first quarter 2020, was $54.1 million, or $0.87 per share, compared to a net loss of $32.6 million, or $0.90 per share, for the same period in 2019, while cash, cash equivalents and marketable securities totaled $346 million as of March 31, 2020.
Catabis expects top-line results in Q4 2020 from fully enrolled edasalonexent global phase 3 PolarisDMD trial in duchenne muscular dystrophy.